Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 28 articles: HTML format

Single Articles

June 2025
1. ZHANG M, Xu Z, Cao Y, Gao C, et al
   Analysis and characterization of extrachromosomal circular DNA in prostate cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
   Cancer Lett. 2025;628:217875.
   PubMed     Abstract available
   
   
   May 2025
2. JIANG H, Zeng Y, Ning W, Hong J, et al
   Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B beta-hydroxybutyrylation.
   Cancer Lett. 2025 May 18:217808. doi: 10.1016/j.canlet.2025.217808.
   PubMed     Abstract available
   
   
   April 2025
3. CAI S, Deng Y, Zou Z, Tian W, et al
   Metformin inhibits the progression of castration resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation.
   Cancer Lett. 2025 Apr 9:217694. doi: 10.1016/j.canlet.2025.217694.
   PubMed     Abstract available
   
   
   February 2025
4. CHAN HY, Wang Q, Howie A, Bucci J, et al
   Extracellular vesicle biomarkers redefine prostate cancer radiotherapy.
   Cancer Lett. 2025 Feb 18:217568. doi: 10.1016/j.canlet.2025.217568.
   PubMed     Abstract available
   
   
   
5. SUBRAMANIAM S, Jeet V, Gunter JH, Clements JA, et al
   Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer.
   Cancer Lett. 2025 Feb 7:217522. doi: 10.1016/j.canlet.2025.217522.
   PubMed     Abstract available
   
   
   January 2025
6. HINDES MT, McElligott AM, Best OG, Ward MP, et al
   Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.
   Cancer Lett. 2025 Jan 2:217441. doi: 10.1016/j.canlet.2025.217441.
   PubMed     Abstract available
   
   
   November 2024
7. LIU R, Zou Z, Zhang Z, He H, et al
   Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC.
   Cancer Lett. 2024;605:217286.
   PubMed     Abstract available
   
   
   
8. MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al
   PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer.
   Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355.
   PubMed     Abstract available
   
   
   
9. STEINER L, Eldh M, Offens A, Veerman RE, et al
   Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
   Cancer Lett. 2024;609:217352.
   PubMed     Abstract available
   
   
   October 2024
10. GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al
    Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and The Role of Circulating Tumor Cells.
    Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310.
    PubMed     Abstract available
    
    
    August 2024
11. HE Q, Zhang Y, Li W, Chen S, et al
    Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
    Cancer Lett. 2024;602:217214.
    PubMed     Abstract available
    
    
    
12. WANG X, Zhang L, Cheng L, Wang Y, et al
    Extracellular Vesicle-derived Biomarkers in Prostate Cancer Care: Opportunities and Challenges.
    Cancer Lett. 2024 Aug 12:217184. doi: 10.1016/j.canlet.2024.217184.
    PubMed     Abstract available
    
    
    
13. LIU D, Wang L, Guo Y
    Advances in and Prospects of Immunotherapy for Prostate Cancer.
    Cancer Lett. 2024 Aug 8:217155. doi: 10.1016/j.canlet.2024.217155.
    PubMed     Abstract available
    
    
    June 2024
14. LIU YN, Liu MK, Wen YC, Li CH, et al
    Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
    Cancer Lett. 2024 Jun 28:217090. doi: 10.1016/j.canlet.2024.217090.
    PubMed     Abstract available
    
    
    
15. CLARK A, Villarreal MR, Huang SB, Jayamohan S, et al
    Targeting S6K/NFkappaB/SQSTM1/Poltheta signaling to suppress radiation resistance in Prostate Cancer.
    Cancer Lett. 2024 Jun 24:217063. doi: 10.1016/j.canlet.2024.217063.
    PubMed     Abstract available
    
    
    
16. LIU C, Chen J, Cong Y, Chen K, et al
    PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
    Cancer Lett. 2024 Jun 18:217068. doi: 10.1016/j.canlet.2024.217068.
    PubMed     Abstract available
    
    
    
17. CHEN HJ, Yu MM, Huang JC, Lan FY, et al
    SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer.
    Cancer Lett. 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.
    PubMed     Abstract available
    
    
    May 2024
18. KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al
    Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.
    Cancer Lett. 2024;593:216954.
    PubMed     Abstract available
    
    
    March 2024
19. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    PubMed     Abstract available
    
    
    
20. RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al
    CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
    Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776.
    PubMed     Abstract available
    
    
    February 2024
21. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    PubMed     Abstract available
    
    
    
22. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    PubMed     Abstract available
    
    
    
23. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    PubMed     Abstract available
    
    
    
24. ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al
    Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer.
    Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657.
    PubMed     Abstract available
    
    
    January 2024
25. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    PubMed     Abstract available
    
    
    November 2023
26. ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al
    Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TbetaRI expression.
    Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468.
    PubMed     Abstract available
    
    
    October 2023
27. WANG C, Wang T, Li KJ, Hu LH, et al
    SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
    Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
    PubMed     Abstract available
    
    
    September 2023
28. SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al
    PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.